Functionalized pyrrolidine inhibitors of human type II α-mannosidases as anti-cancer agents: Optimizing the fit to the active site
Authors:
- Douglas A. KuntzDKDouglas A. Kuntz
- Daniela HoffmanDHDaniela Hoffman
- Robert C. JanzerRJRobert C. Janzer
- Sandrine Gerber-LemaireSGSandrine Gerber-Lemaire
- David R. RoseDRDavid R. Rose
- Lucienne Juillerat-JeanneretLJLucienne Juillerat-Jeanneret
- 1 August 2008
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 16 (15) , 7337-7346
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Structural Basis of the Inhibition of Golgi α-Mannosidase II by Mannostatin A and the Role of the Thiomethyl Moiety in Ligand−Protein InteractionsJournal of the American Chemical Society, 2006
- Synthesis of New Pyrrolidine Derivatives as Inhibitors of a-Mannosidase and of the Growth of Human Glioblastoma CellsHETEROCYCLES, 2006
- The sweet and sour of cancer: glycans as novel therapeutic targetsNature Reviews Cancer, 2005
- Galectins as modulators of tumour progressionNature Reviews Cancer, 2005
- Roles of N-Linked Glycans in the Endoplasmic ReticulumAnnual Review of Biochemistry, 2004
- Glycosidase inhibitors: update and perspectives on practical useGlycobiology, 2003
- Glycosidase mechanismsCurrent Opinion in Chemical Biology, 2002
- Targeting glycosylation as a therapeutic approachNature Reviews Drug Discovery, 2002
- Derivatives of (2R,3R,4S)-2-Aminomethylpyrrolidine-3,4-diol are selective α-Mannosidase inhibitorsBioorganic & Medicinal Chemistry Letters, 2001
- An EXCEL template for calculation of enzyme kinetic parameters by non-linear regression.Bioinformatics, 1998